Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Basiliximab
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Basiliximab
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Basiliximab
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Basiliximab on the MHRA register
Simulect 20mg powder and solvent for solution for injection vials
Novartis Pharmaceuticals UK Ltd
WHO defined daily dose (DDD)
40 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(2)
Immunosuppressive therapy for kidney transplant in children and young people (TA482)
Immunosuppressive therapy for kidney transplant in adults (TA481)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 9 · Randomised trials: 13 · 1997–2026
Showing the 50 most relevant studies, sorted by most relevant.
B. Nashan, R. Moore, P. Amlot, et al.
The Lancet, 1997
O. Thomusch, M. Wiesener, M. Opgenoorth, et al.
Lancet, 2016
Provenzani A, Lape BA, Harp AM, et al.
2025
R. Haynes, P. Harden, P. Judge, et al.
Lancet, 2014
K. Zhao, R. Lin, Z. Fan, et al.
Journal of Hematology & Oncology, 2022
Haixia Fu, Xue-yan Sun, R. Lin, et al.
BMC Medicine, 2024
Y. Liu, P. Zhou, M. Han, et al.
Transplantation proceedings, 2010
C. Dong, Zhuolun Song, Chao Sun, et al.
Transplantation, 2024
G. Martínez-Mier, P. I. Moreno-Ley, L. Budar-Fernández, et al.
Archives of medical research, 2024
P. Keown, R. Balshaw, S. Khorasheh, et al.
BioDrugs, 2012
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
3.2 days
Mechanism
Basiliximab binds with high-affinity to the alpha-subunit (CD25) of the high-affinity IL-2 receptor.
Food interactions
None known
Human targets
2 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Half-life
3.2 days
Volume of distribution
5.1 L
* 4.8 ± 2.1 L [Adult]
Metabolism
Clearance
19 mL
* 17 +/- 6 mL/h [pediatric patients undergoing renal transplantation]…
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 681 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
* 4.8 ± 2.1 L [Adult]
* 17 +/- 6 mL/h [pediatric patients undergoing renal transplantation]
* 31 +/- 19 mL/h [adolescent patients undergoing renal transplantation]
Proteins and enzymes this drug interacts with in the body
ATC L04AC02
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Basiliximab
Additional database identifiers
Drugs Product Database (DPD)
12027
HUGO Gene Nomenclature Committee (HGNC)
HGNC:6008
GenAtlas
IL2RA
GeneCards
IL2RA
GenBank Gene Database
X01057
GenBank Protein Database
33813
Guide to Pharmacology
1695
UniProt Accession
IL2RA_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:6009
GenAtlas
IL2RB
GeneCards
IL2RB
GenBank Gene Database
M26062
GenBank Protein Database
307048
Guide to Pharmacology
1696
UniProt Accession
IL2RB_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72